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Abstract
Background:  Atherosclerosis and coronary heart disease (CHD) are significant contributors to
morbidity and mortality in developed countries. A noted exception is the low mortality of CHD in
France, particularly the southwest region. This phenomenon, commonly referred to as the French
paradox, may be associated with high consumption of red wine. We investigate whether the
cardioprotective activity of red wine may involve the grape skin-derived polyphenol, resveratrol.
We further test the possibility that resveratrol acts by modulating structural and functional changes
in endothelial cells lining the blood vessel wall.
Results:  Bovine pulmonary artery endothelial cells (BPAEC) were incubated with resveratrol,
with and without concurrent exposure to simulated arterial shear stress. Resveratrol significantly
affected proliferation and shape of BPAEC; growth was suppressed and cells became elongated,
based on morphologic analysis of rhodamine-conjugated phalloidin stained F-actin by confocal
microscopy. Using selective signaling inhibitors, we showed that the resveratrol-induced cellular
phenotype was dependent on intracellular calcium and tyrosine kinase activities, and assembly of
actin microfilaments and microtubules, but was unrelated to PKC activity. Exposure to simulated
arterial flow revealed that, whereas controls cells easily detached from the culture support in a
time-dependent manner, resulting in total cell loss after a 5 min challenge with simulated arterial
flow conditions, a significant percentage of the treated cells remained attached to the cultured
plastic coverslips under identical experimental conditions, suggesting that they adhered more
strongly to the surface. Western blot analysis shows that whereas cells treated with 25 µ M and 100
µ M  r e s v e r a t r o l  h a d  n o  c h a n g e  i n  t o t a l  E R K 1 / 2 , t r e a t m e n t  d i d  r e s u l t  i n  a n  i n c r e a s e  i n
phosphorylated ERK1/2, which probably involved stabilization of the active enzyme. An increase in
nitric oxide synthase expression was detected as early as 6 h and persisted for up to 4 days of
treatment.
Conclusions:  Results of our studies show that resveratrol interacts with endothelial cells in vitro
to elicit morphological and structural changes; the observed changes support the interpretation
that resveratrol acts as a cardioprotective agent.
Published: 29 January 2001
BMC Cell Biology 2001, 2:1
This article is available from: http://www.biomedcentral.com/1471-2121/2/1
Received: 22 November 2000
Accepted: 29 January 2001BMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
Background
Atherosclerosis and coronary heart disease (CHD) have
long been considered major contributors to morbidity
and mortality in developed countries [1,2,3]. One noted
exception is the low mortality of CHD in France, particu-
larly the southwest region [4,5,6]. This phenomenon,
commonly referred to as the French paradox, may be as-
sociated with high consumption of red wine [7,8]. A neg-
ative correlation between CHD and alcohol consumption
was first noted 25 years ago, and numerous studies since
have confirmed a statistically significant inverse rela-
tionship between these two factors [9,10,11,12,13,14]. In
vivo studies have shown that wine consumption, partic-
ularly red wine, is more effective in the prevention of
CHD not seen with other forms of alcoholic beverages
[15,16,17]. Accordingly, it has been postulated that natu-
rally occurring components in wine might afford or con-
tribute to its enhanced protection against CHD by
targeting sites that participate in the etiology of CHD, in-
cluding soluble blood components (LDL), cellular blood
elements (platelets), or the vasculature itself (endotheli-
um). Siemann and Creasy proposed that trans-resvera-
trol, a tri-hydroxy stilbene, in red wine exhibits
cardioprotective properties [18] and can inhibit LDL ox-
idation [19], suppress smooth muscle proliferation [20],
induce nitric oxide synthase expression [21] and block
collagen-induced aggregation responses in washed
platelets [22,23,24]. However, relatively few studies
have been performed on the effects of resveratrol on vas-
cular components such as the endothelial cells, which are
known to play a critical role in maintaining the integrity
and functioning of the vascular endothelium. Homeosta-
sis of the vascular endothelium, both with respect to met-
abolic and physiologic activities, can be affected by
overall nutritional status and by specific ingredients in
the diet [25,26,27].
The aims of the present study were to determine changes
resulting from resveratrol:endothelial cell interaction.
We observed that resveratrol induced significant cellular
and biochemical changes in endothelial cells, which were
accompanied by altered functional responsiveness to
conditions simulating arterial flow. Since previous stud-
ies have shown several signaling molecule changes dur-
ing reorganization of the endothelial cell cytoskeleton
accompanying arterial shear stress [28,29,30,31], we
evaluated the same set of biochemical parameters in res-
veratrol-treated cells. Use of selective signaling pathway
inhibitors allowed the demonstration that the cytoskele-
tal changes elicited by resveratrol depended on intracel-
lular calcium and tyrosine kinase activity changes, and
also appeared to be linked to integrity of actin microfila-
ments and microtubule network. Resveratrol treatment
also led to activation of ERK1/2 MAP kinase, similar to
changes induced by shear [30,31]. Thus resveratrol may
act by a mechanism(s) closely resembling that triggered
by shear stress.
Figure 1
Resveratrol treatment produces elongation of BPAEC. Panel A. Example of stellar, cobblestone-like morphology characteristic
of normal BPAECs grown in culture. Panel B. Example of elongated, spindle-shaped morphology characteristic of resveratrol-
treated cells. Here cells were treated with 100 µ M resveratrol and were viewed with 20X objective. Six experiments, each
involving a different preparation of BPAEC, were performed with similar results.BMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
Results
Resveratrol induces morphologic change in endothelial 
cells
Sterilized plastic 18 mm ×  21 mm coverslips were seeded
with BPAEC and treated 24 h later with various concen-
trations of resveratrol. Following an additional 2 day of
culture, the coverslips containing the attached BPAECs
were fixed, stained with rhodamine-phalloidin, and
mounted onto slides for analysis by confocal microscopy.
The polyphenol (100 µ M) had a distinct morphologic ef-
fect, changing the cells from a boxy, cobblestone-like ap-
pearance (panel A, Fig. 1) to an elongated, ellipsoidal
shape with long, tortuous processes (panel B). As little as
25  µ M resveratrol sufficed to induce these cellular
changes, in passage 4-7 cells (compare panel C with pan-
el A, Fig. 2). To quantify the percentages of cells with the
elongated morphology, a minimum of 300 cells in repre-
sentative microscopic field were counted and the results
presented in Fig. 3. The percentage of cells showing the
elongated phenotype is proportional to the concentra-
tion of resveratrol added to the culture. Treatment with
resveratrol also suppressed growth of BPAEC (data not
shown), as we previously reported [21].
Resveratrol treatment leads to increased adherence of 
BPAEC under simulated arterial flow conditions
To test whether functional changes may accompany the
modified morphology, control and 2 day and 100 µ M res-
veratrol-treated cells were exposed to 0 min (control), 2
min, or 5 min of simulated arterial shear stress using a
parallel plate perfusion chamber (see Materials and
Methods). Following the shear challenge, cells remain-
ing attached were scored by staining with rhodamine-
phalloidin, as described. Since the cells were evenly dis-
tributed throughout the area of the coverslip exposed to
flow, representative pictures were taken of the confocal
microscopy fields located directly in the center of the
coverslip, and the number of cells were counted. As can
be seen in Fig. 4, compared to the 0 min sample, a signif-
icant percentage of resveratrol-treated BPAEC remained
attached to the plastic coverslips after 2 min and 5 min
flow challenge. In comparison, under identical experi-
mental conditions, cells adhering to the coverslips de-
creased dramatically in controls, with virtually no cells
remaining after a 5 min simulated flow. These results
suggest that a functional alteration, measured by greater
adherence of cells under simulated arterial flow condi-
tions, accompanied the change in cellular phenotype, fol-
lowing treatment with resveratrol.
Effect of cell signaling inhibitors on cell elongation induced 
by resveratrol
Further insights into the nature of the resveratrol-in-
duced morphologcial changes came from studies using
selective inhibitors for different signaling pathways.
These include: quin2-AM (intracellular [Ca2+]), her-
bimycin A (tyrosine kinases), chelerythrine (PKC), cyto-
chalasin D (actin microfilaments), and nocodazole
(disassembly of microtubules). Cells were treated with
inhibitors, at concentrations indicated in Materials and
Methods, and then exposed to resveratrol. Representa-
tive confocal microscopy fields for both control and res-
veratrol-treated cells were counted for elongated and
non-elongated cells. The inhibitors used noticeably sup-
pressed cell growth (particularly treatment with cytoch-
alasin D and nocodazole), particularly controls not
treated with resveratrol. The degree of growth inhibition
varied, depending on preparations of primary BPAEC.
Interestingly, cells treated with resveratrol, which had to
be reduced to 40 h because of adverse responses of con-
trol cells to inhibitors (see Materials and Methods), af-
forded better growth in samples containing the
inhibitors. Table 1 summarized results averaged from 4
separate experiments, each performed with a different
preparation of primary BPAEC. Since growth of control
cells as well as their response to resveratrol and addition
of inhibitors differed between BPAEC preparations, cells
showing the elongated shape in each experiment were
calculated as a percent of total cells counted (ranging
from 60-700). The numbers obtained in this manner
were used to calculate the mean (%)±  SD, as shown. Ad-
dition of chelerythrine, an inhibitor of protein kinase C,
caused a significant increase in percentage of elongated
cells alone and did not affect morphologic response of
cells to resveratrol. Inhibitors of intracellular [Ca2+] and
tyrosine kinase activity effectively reduced the percent-
age of elongated cells elicited by resveratrol. Results in
Table 1 further showed that cytoskeletal changes elicited
by resveratrol also appeared to be linked to integrity of
actin microfilaments and microtubule network as the
morphologic changes were also substantially lowered in
cells treated with cytochalasin D and nocodazole, which
inhibit formation of actin microfilaments and microtu-
bule network, respectively.
Effect of resveratrol on ERK1/2 activation and eIF4E, 
eNOS expression
Biochemical changes in resveratrol-treated BPAEC were
assessed by western blot analyses. Fig. 5 shows that in
control cells, level of active ERK1/2-P remained relative-
ly constant up to 48 h but showed a precipitous decline
from 48 to 96 h (panel A). Under the same conditions,
levels of total ERK1/2 (panel B), eIF4E (panel C), a
downstream effector of ERK1/ERK2, and actin (panel E)
showed no substantial change at all time points assayed,
in control cells. Treatment with 25 µ M and 100 µ M res-
veratrol prevented the decrease in active ERK1/2-P seen
at 96 h (panel A, last 3 lanes). In addition, these concen-
trations of resveratrol markedly increased eNOS expres-
sion as early as 6-h, which reached maximum inductionBMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
at 48-h, and remained substantially elevated at 96-h
(panel D). Quantification of relative changes of total
ERK1/2, active ERK1/2-P, and eNOS as a function of
time of treatment with two concentrations of resveratrol
is depicted in Figure 6.
Discussion
Results of our studies suggest that resveratrol, an abun-
dant red wine polyphenol, interacts with endothelial
cells in vitro to result in morphologic and functional
changes. The elongated shape, interspersed with long,
tortuous projections displayed by resveratrol-treated
BPAEC (Fig. 1,2,3) has apparent functional significance
since these cells resisted detachment from the plastic
coverslips under simulated arterial shear stress condi-
tions (Fig. 4). The resveratrol-induced cellular changes
could represent a mechanism of minimizing endothelial
damage by shearing forces in vivo. Moreover, resistance
to detachment could also make endothelial cells less like-
ly to dislodge and become part of a growing thrombotic
plug.
Modulation of endothelial cell shape by resveratrol
Size, shape, mutual orientation, and intercellular con-
tacts in endothelium are not incidental and statistic
events, but are precisely and dynamically regulated. Re-
versible change of endothelial cell shape, mutual orienta-
tion of cells in certain directions, changes in intercellular
contacts, are controlled by a number of factors, such as,
cooperative stimulation of the receptors or the systems
of second messengers [32,33], dietary ingredients, e.g.,
retinoids [34], exercise [35,36], and fluid-imposed shear
stress [37,38,39]. For example, endothelial cells are
known to elongate and reorient their cytoskeletons in the
direction of flow as a normal physiological response to
prolonged shear stress [29]. Results of the present stud-
ies show that treatment with resveratrol induces a mor-
phologic change from a stellar to an elongated shape
(Figure 1). It is tempting to speculate that appearance of
such cellular phenotype involves formation of stress fib-
ers, which would rearrange the cytoskeleton in ways that
facilitate better anchoring of the BPAEC to the culture
substratum and contribute to the ability of BPAEC to re-
sist simulated arterial flow challenge. Only studies in the
future would validate such a possibility. It is also inter-
esting to note that the observed changes in resveratrol-
treated BPAEC are similar to that described for EC sub-
jected to arterial shear. We propose that this could repre-
sent a physiologically-relevant mechanism by which
resveratrol, as a polyphenolic constituent of red wine,
contributes to cardioprotection by inducing resistance to
potential damage by shearing forces.
The mechanism underlying this cytoskeletal rearrange-
ment due to shear stress is ill-defined, but it has been
found to be linked to tyrosine kinase activity, levels of in-
tracellular calcium, intact actin microfilaments, and
functional microtubule network, but is independent of
protein kinase C, intermediate filaments, and stretch-
and shear-activated mechanosensitive K+ channels [28].
We therefore sought to determine whether a similar
mechanism could account for the resveratrol-mediated
endothelial shape change. Our approach involved using
a number of selective inhibitors for various signaling
pathway. These studies showed that quin2-AM ([Ca2+]
inhibitor), added together with resveratrol, clearly abol-
ished the endothelial cell shape change induced by the
polyphenol. In contrast, chelerythrine, a PKC inhibitor,
which added alone triggered a significant shape change
in BPAEC, had no effect on resveratrol-elicited morpho-
logical change (Table 1). Analyzed as a whole, these ex-
periments suggest that the change in cellular phenotype,
as a consequence of resveratrol:EC interaction, is de-
pendent on Ca2+, tyrosine kinases, and intact actin mi-
crofilament and microtubules. These results also raise
the possibility that there is cellular heterogeneity within
endothelial cells used in the studies, based on the fact
that a subset displayed exquisite sensitivity to cheleryth-
rine. Overall, these results support the notion that res-
veratrol and shear stress induce elongation of the EC
Table 1: Use of inhibitors to probe the basis for elongation of 
BPAEC induced by resveratrol. These experiments used passages 
4-5 BPAEC cells. The cells on cover slips were incubated with in-
hibitors for 24 h, before 100 µ M resveratrol was added and incu-
bation was continued for an additional 40 h. An exception was 
quin2-AM, which was applied 1 h prior to resveratrol treatment.
Cellular Component 
affected
Controla Cells treated with 100 
µ M resveratrola
% elongated cells % elongated cells
Control 12.90 ±  5.56 33.80 ±  7.50
Intracellular 15.80 ±  1.42 11.73 ±  1.89
[Ca2+]
PKC 22.47 ±  3.58 37.63 ±  6.17
Tyrosine kinases 9.65 ±  1.05 10.55 ±  1.05
Actin
Microfilaments 10.40 ±  2.60 12.25 ±  3.75
Actin
Microtubules 4.17 ±  4.94 8.60 ±  6.53
a Results in this table were averaged from 4 separate experiments, each 
performed with a different preparation of primary BPAEC's. Since 
growth of control cells as well as their response to resveratrol and ad-
dition of inhibitors differed between BPAEC preparations, cells showing 
the elongated shape in each experiment were calculated as a percent of 
total cells counted (ranging from 60-700). The numbers obtained in this 
manner were used to calculate the mean (%)±  SD, as shown.BMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
cytoskeleton via an overlapping outside-in signaling
mechanism.
Prolonged shear stress leading to mechanotransduction
signaling has been shown to activate the MAP kinase
pathway in EC. Activation of ERK1 and ERK2, the major
components of the MAPK pathway, presumably induces
shear-specific transcription factors, such as c-fos/c-jun
and NFκ B, ultimately leading to changes in gene expres-
sion [30,31]. Western blot analysis of control and 25 µ M
and 100 µ M resveratrol-treated BPAEC showed that
there was no increase in active ERK 1/2 at the 6 h and 2
day time points. Rather, the decline in activated ERK 1/
2 seen from days 2 to 4 of control cells, was effectively
suppressed by resveratrol, suggesting that the polyphe-
nol may act by affecting the stability of active ERK1/2
(Figure 6). This may involve modulation of MAPK phos-
phatase-1 (MKP-1), a member of the immediate-early re-
sponse gene product functioning as a dual specificity
phosphase to reverse MAPK [40,41,42,43,44], by resver-
atrol. Previously, it has been reported that MKP-1 is rap-
idly induced in rat carotid arterial wall following balloon
catheter injury [45]. Since no noticeable change in active
ERK1/2 occurred at the 6 h or 2 day time points, where
morphological changes clearly became visible, following
treatment with resveratrol, it seems unlikely that the ac-
tivation of MAPK is directly linked to the observed mor-
phologic changes.
Responses of cultured endothelial cells to arterial shear 
stress
Another significant contribution of the present research
is the demonstration that resveratrol promoted a greater
adherence of BPAEC to the cultured vehicle in vitro. In
vivo, such a cellular property could make endothelial
cells less likely to dislodge to become part of a growing
thrombotic plug. Restricted detachment could also imply
that there is less degeneration of the endothelial cell
monolayer, which, in turn, would reduce the exposure of
the underlying subendothelial matrix components,
thereby making platelet adhesion and aggregation less
likely. The mechanism(s) responsible for the resveratrol-
Figure 2
Morphology of passage 6 BPAEC treated with the following concentrations of resveratrol: A) 0 µ M; B) 10 µ M; C) 25 µ M; D) 50
µ M. Cells were stained with rhodamine-phalloidin and viewed under 10X confocal microscopy. The same experiment was
repeated three times, using passages 6-7 cells from two different preparation of BPAEC.BMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
induced cellular properties remain to be further investi-
gated. One possibility centers on modulation of the
number of focal contact adhesion sites, and/or the effec-
tive redistribution of the focal contacts, as well as the in-
creased production of the EC-specific integrin complex,
by resveratrol, all of which could contribute to the cardi-
oprotective mechanism of this polyphenol. However, it
should be emphasized that these experiments involved
growing EC on plastic, not on layers of subendothelial
matrix components such as collagen or fibrinogen. The
latter experimental format simulating a more physiolog-
ically relevant subendothelial matrices may yield vastly
different results. These possibilities warrant further in-
vestigation.
Induction of eNOS and modulation of EC growth by res-
veratrol
The endothelial cell lining of the blood vessel is extreme-
ly sensitive to damage from reactive oxygen species
(ROS), the results of which are losses of both microvas-
cular metabolic function and barrier properties [46]. To
minimize such oxidant damage, cells rely on the produc-
tion of nitric oxide (NO) by the enzyme nitric oxide syn-
thase (eNOS). Biological functions attributed to NO
include vasodilation [47], inhibition of platelet adhesion
and aggregation [48], reduction of expression of adhe-
sion molecules and chemokines [49,50,51,52], and sup-
pression of cell growth and migration [53,54]. Therefore,
we investigated whether resveratrol treatment could lead
to increased eNOS expression in endothelial cells. We
determined that resveratrol treatment did induce eNOS
expression at all time points tested (6 h, 2 days, and 4
days). These results agreed with a previous report from
this laboratory [21]. The peak expression of eNOS oc-
curred at 2 days in 100 µ M resveratrol-treated cells.
These findings could mean that dietary resveratrol is ca-
pable of providing a gradual yet sustained increase in
NO. The ability of resveratrol to induce S/G2 growth ar-
rest [20,21] suggests an additional mechanism for cells
to rapidly and efficiently repair any endothelial cell dam-
age. Overall, the collective effect of resveratrol would be
to decrease endothelial injury and exposure of the suben-
dothelial matrix, which would lessen the probability of
Figure 3
Resveratrol treatment causes a dose-dependent increase in BPAEC elongation. Cells from representative confocal microscopy
fields from passages 5 and 6 were visually evaluated for overall change in cell morphology. A minimum of 300 cells were scored
for each treatment condition.BMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
formation of atherosclerotic plaques and the develop-
ment of CHD [53,54,55].
Conclusions
Our studies suggest that resveratrol interacts with en-
dothelial cells in vitro to elicit morphological and func-
tional changes. Specifically, resveratrol induced an
elongated shape, interspersed with long, tortuous pro-
jections, in cultured BPAEC. Treated cells resisted de-
tachment from the plastic coverslips under simulated
arterial shear stress conditions. These results, combined
with data from our previous studies, provide additional
support for the notion that resveratrol acts as an anti-
Figure 4
Passage 7 BPAEC were treated with the following concentration of resveratrol as described in Materials and Methods and then
subjected to simulated arterial flow durations, respectively. A) 0 µ M, 0 min (control); B) 100 µ M; C) 0 µ M, 2 min; D) 100 µ M,
2 min; E) 0 µ M, 5 min; F) 100 µ M, 5 min. Similar results were obtained using passage 6 BPAEC (data not shown). Four experi-
ments, using passages 6-7 cells from two different preparation of BPAEC, were performed.BMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
atherosclerotic agent. Whether these findings can be ex-
trapolated to humans require further study.
Materials and Methods
Stock solution (12.5 mM) of resveratrol (Sigma Chemical
Co.) was prepared in DMSO and stored at -20° C. For
treatment, the resveratrol was diluted in RPMI 1640 and
added to cultures to give the desired final concentra-
tions. Untreated cultures received the same amount of
the carrier solvent (0.2% DMSO). The rhodamine-conju-
gated phalloidin, used to detect F-actin, was purchased
from Molecular Probes, Eugene, OR, and stored at 4° C in
methanol. Before use, the solvent methanol was evapo-
rated using N2 gas and the F-actin probe was resolubi-
lized in TBS (Tris-buffered saline).
Cell culture and treatment with resveratrol
The BPAEC isolated from the distal main intrapulmo-
nary artery of calf lungs were cultured in minimal essen-
tial medium (MEM) supplemented with 15% fetal bovine
serum and containing D-valine as previously described
[56]. Plastic coverslips on which the cells were cultured
were sterilized by washing in ethanol, followed by rinsing
three times in MEM and 15 min exposure to UV radia-
tion. The coverslips were placed in 6-well tissue culture
plates, and 2 ml of the cells, at an initial density of 1 ×  105
cells/ml, were added to each of the wells. Twenty-four h
after seeding, the coverslips were treated with 0,10, 25,
50, and 100 µ M resveratrol and maintained for 2 days at
37° C until they were fixed and stained for confocal mi-
croscopy.
Preparation and staining of slides
Coverslips containing adhered BPAEC were washed for 5
min in TBS, fixed with 5% glutaraldehyde in 0.1 M ca-
codylate (pH 7.4) for 15 min, washed again for 5 min in
TBS, then stored in 0.1 M cacodylate/7% sucrose at 4° C
until staining. Cells were permeabilized with 0.1% Triton
X-100/TBS for 3 min, washed twice with TBS, blocked
twice for 3 min with 0.1% bovine serum albumin in TBS,
and incubated with rhodamine-conjugated phalloidin
for 20 min. Routinely, 5 µ l of rhodamine-phalloidin, dis-
solved in 200 µ l TBS, was used for each coverslip stained.
The coverslips were wash with 0.1% BSA/TBS for 3 min,
Figure 5
Biochemical changes in resveratrol-treated BPAEC. BPAEC were treated with the indicated concentrations of resveratrol and
lysed after 6, 48, and 96 h, respectively. Lysates were run under 10% SDS-PAGE, and probed with antibodies for the various
target proteins. Panel A. Changes in activated ERK1/2-P (representative of 3 experiments). Panel B. Changes in ERK1/2 (repre-
sentative of 2 experiments). Panel C. Changes in eIF-4E. Panel D. Changes in eNOS. Panel E. Changes in actin. Lanes 1,4,7 cor-
respond to control at 6, 48, and 96 h; lanes 2,5,8 correspond to BPAEC treated with 25  µ M resveratrol for 6, 48, and 96 h;
lanes 3,6,9 correspond to BPAEC treated with 100 µ M resveratrol for 6, 48, and 96 h. The results represent the average of
two experiments, each analyzed in duplicate or triplicate.BMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
Figure 6
Time-dependent relative changes in expression of total ERK1/2, active ERK1/2, and eNOS. Intensity of signals corresponding to
total ERK1/2 (panel A), active ERK1/2 (panel B), and eNOS (panel C) obtained by western blot analysis, similar to those shown
in Figure 5, was quantified by actin-adjusted image analysis and plotted as a function of time of treatment with 25 µ M and 100
µ M resveratrol. The control value at 6 h was set at 100. The results represent the average of two experiments, each analyzed
in duplicate or triplicate.BMC Cell Biology (2001) 2:1 http://www.biomedcentral.com/1471-2121/2/1
then mounted in an inverted position onto TBS-contain-
ing beveled glass slides and sealed with clear nail polish.
Perfusion
A parallel plate perfusion chamber as described previ-
ously [57] was used to generate simulated arterial flow
conditions. The chamber consisted of three pieces: two
rectangular slabs and a central knob with a depression
that fits 18 by 21 mm coverslips. The depression contain-
ing the coverslip was placed perpendicularly to the flow
of perfusate. A laminar arterial shear rate of 650 s-1 was
achieved based on the dimensions of the flow chamber
slit and a constant flow rate of 10 ml/min. After preincu-
bation at 37° C, minimal medium was drawn directly by
an eight roller peristaltic pump through the perfusion
chamber containing the BPAEC-covered coverslip posi-
tioned 70 mm from the inlet valve at a rate of 10 ml/min
for either 2 min or 5 min. A recirculating system was em-
ployed to recycle the medium after passing through the
chamber.
Confocal microscopy
Prepared slides containing adhered BPAEC were exam-
ined using a BioRad confocal microscope. The cells were
imaged following excitation of rhodamine-phalloidin
with an argon laser beam at a wavelength of 554 nm us-
ing either an inverted- or an uprighted-staged micro-
scope equipped with either a 10X or a 20X oil-free
objective and an epifluorescent illumination attachment.
Cells viewed in representative field screen captures were
counted manually for cell morphology and classified as
either normal or elongated.
Inhibitor study
Passages 4-5 BPAEC were seeded on plastic coverslips as
described above. Inhibitor concentrations were the same
as in [28]. Stock solutions were prepared by dissolving
the inhibitors in DMSO. The inhibitors used and their
stock solutions were as follows: quin2-AM (Sigma, 2
mM), herbimycin A (GibcoBRL, 0.175 mM), cheleryth-
rine (Sigma, 0.4 mM), cytochalasin D (Sigma, 8 µ M),
nocodazole (Sigma, 0.66 mM). Quin2-AM, herbimycin
A, chelerythrine, and cytochalasin D were stored at -
20° C, and nocodazole was stored at 4° C. The stock solu-
tions were diluted 1:200 in MEM to give the following fi-
nal concentrations: quin2-AM (10 µ M), herbimycin A
(875 nM), chelerythrine (2 µ M), cytochalasin D (40 nM),
nocodazole (3.3 µ M). Inhibitors were applied 24 h prior
to the addition of resveratrol, except for quin2-AM,
which was applied 1 h prior to resveratrol treatment.
Since cells treated with various inhibitors grew less well,
compared to controls, treatment with 100 µ M resveratrol
was reduced to approximately 40 h. Fixing and staining
of cells for confocal microscopy was as described above.
Western blot analysis
Control and treated cells were lysed by repeated freeze-
thaw cycles with buffer containing 10 mM HEPES (pH
7.5), 1.5 mM Mg(OAc)2, 1 mM dithiothreitol (DTT), 0.5%
NP40, 5% glycerol, 0.5 mM phenylmethylsulfonyl fluo-
ride, and 10 µ g/ml each of the protease inhibitors apro-
tinin, pepstatin, and leupeptin. Cell-free extracts were
obtained by centrifugation in a microcentrifuge. Lysates
(7-10 µ g) from control and treated cells were separated
on 10% SDS-PAGE. The separated proteins were trans-
ferred to nitrocellulose membranes, and the membranes
were incubated with the respective primary and second-
ary antibodies. The monoclonal primary antibodies used
and their dilutions were as follows: Phosphorylated, ac-
tive ERK1/2-P (RBI/Sigma, 1:1000), total ERK1/2 (RBI/
Sigma, 1:1000), eIF4E (Santa Cruz, 1:250), eNOS (Sigma
1:1000). Membranes were probed with alkaline phos-
phatase-conjugated IgG (Santa Cruz, 1:1500) or horse-
radish peroxidase-conjugated IgG (Santa Cruz, 1:2000).
Specific immunoreactive bands were identified by color
reaction or enhanced chemiluminescence, respectively.
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